← Markets

Integer Holdings Corporation

ITGR · NYSE

Market closed$95.42$-4.20 (-4.22%)After hours $95.42 · 0.00%

Key statistics

Previous close$99.62
Open$98.50
Day high$99.67
Day low$95.23
52-week high$116.31
52-week low$62.00
Market cap3.24B
Volume397.51K
Average volume549.21K
P/E ratio15.15
Forward P/E—
EPS6.30
Dividend yield0.00%

Market context

Why it moved

Integer Holdings (ITGR) fell sharply after Intuitive Surgical warned that changes to insurance coverage could slow U.S. medical procedure growth, sparking broad fears of a sector-wide demand slowdown that weighed on medical device companies across the industry.

MarketbeatMarketbeatYahoo FinanceInstagramInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Integer Holdings closed sharply lower, declining alongside several medical device peers after Intuitive Surgical warned that shifting insurance coverage could dampen U.S. procedure volumes, sparking sector-wide concerns about near-term demand. The selloff compounded existing investor attention on Integer's strategic review process — which has drawn private equity interest and analyst speculation about a potential sale — as well as its Q1 results that featured flat year-over-year revenue and lowered full-year guidance. Truist Securities raised its price target to $110 from $97 the prior day, maintaining a Buy rating, though the broader sector headwinds overshadowed that positive catalyst.

-4.216

July 17, 2026Integer Holdings surged over 4% during the session after Truist Securities raised its price target to $110 from $97 while maintaining a Buy rating, providing a bullish catalyst for the medical device contract manufacturer. The analyst upgrade came amid broader healthcare sector strength — UnitedHealth Group's Q2 earnings beat and raised guidance lifted the XLV healthcare ETF — partially offsetting an ongoing securities investigation by Bronstein, Gewirtz & Grossman into potential shareholder claims. In after-hours trading, shares have pulled back nearly 2% to around $97.70, with the stock trading near its revised fair value estimate as investors weigh softer full-year guidance from Q1 results against improving margin trends.

4.2486

July 15, 2026Integer Holdings gained over 2% on July 15, rebounding from the prior session's 3.2% decline, as investors reassessed valuation after GuruFocus flagged the stock as undervalued following that pullback. A Q1 earnings review highlighted that Integer beat revenue estimates by 3.1% and its shares are up ~15% since reporting, though a securities investigation by Bronstein, Gewirtz & Grossman into potential claims on behalf of shareholders adds an overhang. The broader medical device sector faced headwinds from J&J's medtech miss and notable declines in peers like Stryker and Abbott, though UBS upgrading healthcare as a key allocation target offered some sector-level support.

2.4113

July 14, 2026Integer Holdings fell sharply, underperforming the broader healthcare sector as a securities investigation by Bronstein, Gewirtz & Grossman weighed on sentiment alongside broader sector headwinds. The healthcare space faced pressure heading into a critical earnings week — with Abbott also closing down over 3% on medical device concerns — while analyst reports flagged Integer's flat revenue outlook, modest ROIC of 5.4%, and a full-year EPS guidance miss in Q1 as reasons to remain cautious on the stock.

-3.1853

July 14, 2026Integer Holdings closed up nearly 3%, outperforming the broader healthcare sector (XLV) and the S&P 500, which both faced pressure from escalating U.S.-Iran tensions and rising oil prices. The gain came amid a notable securities investigation disclosure—law firm Bronstein, Gewirtz & Grossman announced it is probing potential claims on behalf of ITGR stockholders—while recent insider filings showed the newly appointed EVP of Operations received routine RSU grants totaling 5,424 units. With Q2 earnings season kicking off and healthcare sector earnings expected to face a headline 9% decline (largely driven by Gilead's accounting quirk), Integer's move higher stands out as investors assess the medical device sub-sector's relative resilience.

2.8822

July 10, 2026Integer Holdings closed up nearly 2%, outperforming the healthcare sector (XLV ended the day slightly lower) as investors weighed Citi's maintained Hold rating with a $96 price target alongside an insider RSU grant to the EVP of Operations. The medtech contract manufacturer's Q1 beat — revenues of $439.6 million, topping estimates by 3.1% — continues to support sentiment, with shares up roughly 10% since that report, underpinned by stable cardiovascular procedure volumes and aging-population tailwinds that drive demand for its catheter and guidewire product lines.

1.8815

July 8, 2026Integer Holdings closed modestly lower, edging down amid a broad market risk-off session triggered by renewed U.S.-Iran military exchanges and surging oil prices after President Trump declared the interim peace deal 'over.' Despite the macro headwinds, company-specific sentiment remained constructive: Citigroup recently raised its price target on Integer to $96 (from $92) while maintaining a Neutral rating, and the healthcare sector posted its second consecutive week of market-leading performance with XLV up over 5%. Integer's cardiovascular and vascular product lines — including guiding catheters like the AccuFlex 7F — continue to benefit from stable procedure volumes and aging-population tailwinds, supporting the long-term OEM outsourcing thesis.

-0.8161

July 7, 2026Integer Holdings closed modestly lower as broader healthcare sector pressure weighed on medical device stocks, with the S&P 500 also retreating on the session. While the XLV healthcare ETF remains near its 52-week high following back-to-back weeks as the top-performing S&P 500 sector, Integer's peer Enovis (ENOV) surged 15% on a Medicare reimbursement catalyst, highlighting diverging fortunes within medtech. Healthcare earnings are projected to decline year-over-year this quarter, adding a cautious backdrop for the sector.

-1.606

Simply Wall Street · July 16, 2026Is Integer Holdings (ITGR) Fairly Valued As Weaker Full Year Guidance Clouds Q1 Results?marketscreener.com · July 16, 2026Truist Securities Adjusts Price Target on Integer Holdings to $110 From $97, Maintains Buy RatingSeeking Alpha · May 21, 2026Integer Holdings: Rare Public Asset Soon To Be SoldStock Titan · April 30, 2026Medical device supplier Integer explores sale or merger optionsGlobeNewswire · April 30, 2026Integer Announces Strategic Review to Maximize Stockholder ValuePR Newswire · January 30, 2026Integer Holdings Corporation Securities Fraud Class Action Result of Overstated Demand and 32% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCPR Newswire · January 29, 2026INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Integer Holdings Corporation of Class Action Lawsuit and Upcoming Deadlines - ITGRInvesting.com · December 18, 2025Integer stock rises after activist investor reportedly builds stake and urges sale By Investing.com
Benzinga · July 16, 2026Truist Securities Maintains Buy on Integer Holdings, Raises Price Target to $110
Benzinga · July 8, 2026Citigroup Maintains Neutral on Integer Holdings, Raises Price Target to $96
Benzinga · May 28, 2026Citigroup Maintains Neutral on Integer Holdings, Raises Price Target to $92
Mt Newswire · May 13, 2026Integer's Strategic Review Alongside Private Equity Interest Limits Downside to Numbers, Oppenheimer Says
Mt Newswire · May 13, 2026Oppenheimer Upgrades Integer Holdings to Outperform From Market Perform, Price Target is $115
Benzinga · May 13, 2026Oppenheimer Upgrades Integer Holdings to Outperform, Announces $115 Price Target
Mt Newswire · May 4, 2026Research Alert: CFRA Reiterates Hold Rating On Shares Of Integer Holdings Corporation
Benzinga · May 1, 2026These Analysts Revise Their Forecasts On Integer Holdings After Q1 Results

Peers

S&P 500SPX · $7,457.69-1.01%Medtronic plcMDT · $83.20-0.43%Boston Scientific CorporationBSX · $44.03-1.32%Stryker CorporationSYK · $319.87-3.42%Smith & Nephew plcSN.L · 1,151.00-1.03%ConvaTec Group PlcCNVVY · $11.59+1.05%Enovis CorporationENOV · $27.07-3.56%Baxter International Inc.BAX · $22.61-3.17%Insulet Corp.PODD · $164.06-0.23%Globus Medical, Inc.GMED · $77.00-4.83%Merit Medical Systems, Inc.MMSI · $73.99-2.06%Inspire Medical Systems, Inc.INSP · $50.60-1.82%